Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
Appointed director
|
|
Zomedica Corp. (ZOM)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/10/2023 |
8-K
| Quarterly results |
| 05/11/2023 |
8-K
| Quarterly results |
| 11/14/2022 |
8-K
| Quarterly results |
| 08/15/2022 |
8-K
| Quarterly results |
| 05/10/2022 |
8-K
| Quarterly results |
| 11/12/2021 |
8-K
| Quarterly results |
| 08/11/2021 |
8-K
| Quarterly results|
Docs:
|
"Zomedica Announces Second Quarter 2021 Financial Results TRUFORMA® Instrument Placement Program Implemented to Incentivize Future Assay Sales ANN ARBOR, Mich., Aug. 11, 2021 -- Zomedica Corp. , a veterinary health company creating point-of-care diagnostics products for dogs and cats, today reported consolidated financial results for the three and six months ended June 30, 2021. Amounts, unless specified otherwise, are expressed in U.S. dollars and presented under accounting principles generally accepted in the United States of America . Robert Cohen, Chief Executive Officer of Zomedica stated that, “I fully understand and appreciate that what all of our stakeholders, both internal and external, want to see is continued execution on our goals and the building of increased value in our busin..." |
|
| 05/12/2021 |
8-K
| Quarterly results |
| 11/12/2020 |
8-K
| Quarterly results|
Docs:
|
"Zomedica Announces Third Quarter 2020 Financial Results ANN ARBOR, Mich., Nov. 12, 2020 -- Zomedica Corp. today reported consolidated financial results for the third quarter ended September 30, 2020. Amounts, unless specified otherwise, are expressed in U.S. dollars and presented under accounting principles generally accepted in the United States of America . Summary Third Quarter 2020 Results Zomedica recorded net loss and comprehensive loss for the three and nine months ended September 30, 2020 of approximately $5.0 million, or $0.01 per share, and approximately $12.7 million, or $0.04 per share, compared to a loss of approximately $2.8 million or $0.03 per share, and approximately $17.0 million, or $0.16 per share, for the three and nine months ended September 30, 2019. Research and de..." |
|
| 08/10/2020 |
8-K
| Quarterly results |
| 05/11/2020 |
8-K
| Quarterly results |
| 11/12/2019 |
8-K
| Quarterly results |
| 08/08/2019 |
8-K
| Quarterly results |
| 05/10/2019 |
8-K
| Quarterly results|
Docs:
|
"Zomedica Announces First Quarter 2019 Financial Results ANN ARBOR, Mich., May 10, 2019 -- Zomedica Pharmaceuticals Corp. , a veterinary diagnostic and pharmaceutical company, today reported consolidated financial results for the first quarter ended March 31, 2019. Amounts, unless specified otherwise, are expressed in U.S. dollars and presented under accounting principles generally accepted in the United States of America . “During the quarter, we continued to advance the development of our unique product pipeline of novel diagnostics and innovative therapeutics,” said Gerald Solensky Jr., Chairman and CEO of Zomedica. Corporate Highlights" |
|
| 11/13/2018 |
8-K
| Quarterly results |
| 08/09/2018 |
8-K
| Quarterly results|
Docs:
|
"Zomedica Pharmaceuticals Corp. Announces Second Quarter 2018 Financial Results ANN ARBOR, Mich., Aug. 09, 2018 -- Zomedica Pharmaceuticals Corp. , a veterinary diagnostic and pharmaceutical company, today reported consolidated financial results for the second quarter ended June 30, 2018. Amounts, unless specified otherwise, are expressed in U.S. dollars and presented under accounting principles generally accepted in the United States of America . “Strategically, we have made significant progress in advancing our product pipeline with the addition of our innovative point-of-care diagnostic product, ZM-020,” said Gerald Solensky, Jr., Chairman and CEO of Zomedica. “This new product, along with others in our pipeline, are focused on bringing best-in-class solutions to clinical veterinarians ..." |
|
|
|